

IBD RESPONSE


CD META RESPONSE

Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis



Chris Lamb

IBD Investigators Day 29th January 2024

Predictive modelling



Biorepository




IBD patients



Planned to commence advance therapy for IBD:


anti-TNF α , anti- α 4 β 7, anti-IL12/23, anti-IL23, JAKi, S1PR modulator

(newly licensed, early access and compassionate use medicines included)



Recruitment

Total = 469 (IBD-R: 354, CD-metaR: 95, Tissue microbiome sub study: 20)



Lots to celebrate!

Sites

- 40 Trusts open
- >250 trained research staff
- 9 NIHR Associate PIs


Additional funding since last BSG investigators meeting

- Costed extension
- Expansion of scRNAseq
- Expansion of dietary analysis

Sample number, quality and data return

- 868 stool sets
- 564 blood sets (492 prepped for scRNAseq)
- 90% data completion at week 14

Response and remission rate data rolling in as more patients reach week 14



Thank you to all our sites & investigators!

ibd.response@newcastle.ac.uk
christopher.lamb@newcastle.ac.uk

@IBDResponse